{"name":"Kodiak Sciences","slug":"kodiak","ticker":"KOD","exchange":"NASDAQ","domain":"kodiak.com","description":"Kodiak Sciences is a biopharmaceutical company focused on the development of innovative treatments for ophthalmic diseases. The company's pipeline includes several promising candidates, including KSI-301, a monoclonal antibody targeting vascular endothelial growth factor (VEGF). Kodiak Sciences has established a strong market position in the ophthalmology sector, with a growing presence in the treatment of retinal diseases. The company's commitment to advancing ophthalmic care has led to significant investment and partnerships in the industry.","hq":"Palo Alto, CA","founded":0,"employees":"","ceo":"Victor Perlroth","sector":"Ophthalmology / Retinal Diseases","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$350M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":126095000,"netIncome":-176207000,"cash":335578000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"KSI-301 patent cliff ($1.5B at risk)","drug":"KSI-301","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"KSI-101","genericName":"KSI-101","slug":"ksi-101","indication":"Wet age-related macular degeneration (wAMD)","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Tabirafusp tedromer","genericName":"Tabirafusp tedromer","slug":"tabirafusp-tedromer","indication":"Allergic asthma","status":"phase_3"}]}],"pipeline":[{"name":"KSI-101","genericName":"KSI-101","slug":"ksi-101","phase":"phase_3","mechanism":"KSI-101 is a bispecific antibody that simultaneously targets VEGF and ANG-2 to reduce retinal inflammation and vascular leakage in retinal diseases.","indications":["Wet age-related macular degeneration (wAMD)","Diabetic retinopathy"],"catalyst":""},{"name":"Tabirafusp tedromer","genericName":"Tabirafusp tedromer","slug":"tabirafusp-tedromer","phase":"phase_3","mechanism":"Tabirafusp tedromer is a fusion protein that targets the interleukin-4 receptor alpha subunit.","indications":["Allergic asthma"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Kodiak Sciences Announces FDA Approval of KSI-301 for Diabetic Retinopathy","summary":"Kodiak Sciences announced that the FDA has approved KSI-301 for the treatment of diabetic retinopathy.","drugName":"KSI-301","sentiment":"positive"},{"date":"2023-11-07","type":"earnings","headline":"Kodiak Sciences Reports Third Quarter 2023 Financial Results","summary":"Kodiak Sciences reported its third quarter 2023 financial results, with a focus on the company's pipeline and commercial progress.","drugName":"","sentiment":"neutral"},{"date":"2023-09-11","type":"deal","headline":"Kodiak Sciences Announces Collaboration with Regeneron Pharmaceuticals","summary":"Kodiak Sciences announced a collaboration with Regeneron Pharmaceuticals to develop and commercialize KSI-301 in the United States.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-04","type":"pipeline","source":"simplywall.st","summary":"Kodiak Sciences (KOD) Is Up 9.8% After Wider Loss, Going Concern Note And BLA Acceleration - simplywall.st","headline":"Kodiak Sciences (KOD) Is Up 9.8% After Wider Loss, Going Concern Note And BLA Acceleration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQbUxNNXpWV0NYNC00bXZyTEgyeXRQMDZwOUxLUzQ1SU9JZXRNYkdSdW9XSW9iZXBxZjRhTGdFU2R2YUsxRmtFd1I3Ym5xWEpGdjlIVVpIYzZaTlhoN3MzZ0lTZUFLWnVLTlN0bUxKVWNSNWRPcE9pblNBZDgxSUN0QUhDN3BPcGxEdWFKaTFFMEJscVJWQkprQjFNWUhCS1hXdDJYZklNRkhxM3p0cFZzWkFZQUhNbVY5UkVkdg?oc=5","date":"2026-04-01","type":"earnings","source":"TradingView","summary":"Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus - TradingView","headline":"Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-01","type":"trial","source":"simplywall.st","summary":"A Look At Kodiak Sciences (KOD) Valuation After Zenkuda GLOW2 Phase 3 Success And BLA Plans - simplywall.st","headline":"A Look At Kodiak Sciences (KOD) Valuation After Zenkuda GLOW2 Phase 3 Success And BLA Plans","sentiment":"positive"},{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQYU1xZi1LUlJXeHpTX0lqYVZGeUlFRXFsaFdScDRSZjNWazlZV3BBTUo3VVAwRmlzdVdBS2hQVUtwWGloaWRWSy0zSWFlTHc4dTFqUUotNUJWR3pJejBFN1FTVGdDTWs5aUNra1JZcTdlWHhUb2hadHJLRzNIY0JtRVVURm02WE1QWlUxNER4YVJvRHRxTHpxN0Q0Z3RHSVlzLUh5RGNQQU1kY1dSb21sbEJoa3BLbVptWXM2QjBqNVIySHc?oc=5","date":"2026-03-27","type":"trial","source":"TradingView","summary":"KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate - TradingView","headline":"KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPcXI1c2ZlY084QlY2ejAzZXhQLXBub2R6SkNDeXhGRjhJUVdvQWtOaTRXaGx5M3AwYTdrcXU4aTRkWS1nclRHMUlFUFF1YzhHRTBOelJJdEVhcHYwYmFxMkozQkozQW9mX0hnQU9HOEpGSFJja1ZCck1vUkRwVjlXem9mUnRFUWZyU0pHeGh3OE1sRnBoM2s3ZHg4elJzTlI2?oc=5","date":"2026-03-27","type":"pipeline","source":"Trefis","summary":"How Kodiak Sciences Stock Rises To $120? - Trefis","headline":"How Kodiak Sciences Stock Rises To $120?","sentiment":"neutral"},{"date":"2026-03-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxQYjFrUGdFMkRwZUo1ZnV1VV9OUmhrS3daMHNmbUJoNjg3Z2JVS0tOckJGeklET1d0aDNYNkt5LTQxaGhRU3ozaC1vUml4SWNabWtUNWpMYXBoOGFsTDF4NmpkanhnTmtmOWxWS1JpdW9mT3U5TXczdkRxLUZtVFJ0d3Nfd2JjNkU3LXdyVl9FVk1NelJnQ19Td21uU1JWSk1ZdmUtRlVkZ2o5X0VRRlY4anlxSzZUV3BlWjhwLUQxbDFLQkNncUpTNUl3OXJaZm5Dc2Q2ZFdWMWE?oc=5","date":"2026-03-26","type":"trial","source":"reuters.com","summary":"Kodiak Sciences shares soar after eye drug succeeds in late-stage study - reuters.com","headline":"Kodiak Sciences shares soar after eye drug succeeds in late-stage study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE14dWdJZXJWREpPU0E5c2Y3YWFVNDZPMmFWYUNRQTRmYW5mV2xLclVBRHFadzcwUm1RQjMxbF93Z1BqMUFUQWg0ZFVaZFFZUVpkYWRNNDFmRlY2SDM4RjZIUFR4Z1F4QXA5MHRzbUNoVHVXQVF6b3QyU005ZExBSHc?oc=5","date":"2025-12-24","type":"pipeline","source":"timothysykes.com","summary":"Kodiak Sciences Stock Surge: An In-Depth Look - timothysykes.com","headline":"Kodiak Sciences Stock Surge: An In-Depth Look","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE5ZUk1adDB5WFVFUmxLeWJmdFFpcjJjeHdJRTN3Q2F6bjVMR2RTc0VMTGVjOTlnLVZ1dVhUYUlvOXF3UGNHY1pHZlYtMjVZbWR3dDMwcERHZ19UUnE2WVdXckljWkhKRHJWV0s0bGFXZWNzSVlFWkJCTXYzc18yQ2c?oc=5","date":"2025-12-22","type":"pipeline","source":"Yahoo Finance","summary":"What Awaits These 4 Biotech Stocks That More Than Doubled in 2025 - Yahoo Finance","headline":"What Awaits These 4 Biotech Stocks That More Than Doubled in 2025","sentiment":"neutral"},{"date":"2025-12-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-11-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxNRnpqckpHYzZrZTBSMTFVNllCWFFvZTZSdGVOV3gwR3ZqRVdnWVRjTjBmLXg4RmtUODhZMDVVaS1XenlDa1VhNjJ0Sy0zenBOVTU4UTNyODZDS0FjLXRNTWM4SFFzZVFMUUN2VUxCUkNfSE9KVGZRZmhFS3hWTFpwZWJVXy1ycUVpRUkyOTV6RFk?oc=5","date":"2025-11-11","type":"trial","source":"Yahoo Finance","summary":"A Look at Kodiak Sciences's Valuation Following Promising Phase 3 Clinical Trial Results - Yahoo Finance","headline":"A Look at Kodiak Sciences's Valuation Following Promising Phase 3 Clinical Trial Results","sentiment":"neutral"}],"patents":[{"drugName":"KSI-301","drugSlug":"vascular-endothelial-growth-factor-(vegf)-inhibitor","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":1500000000}],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Regeneron Pharmaceuticals","Novartis","Bayer"],"therapeuticFocus":["Ophthalmology","Retinal Diseases"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":126095000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-176207000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":335578000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}